

The Economic and Legal Problems With PBM Pharmacy Ownership Bans
In The National Law Review, CFJ's Jeffrey Depp argues that state bans on PBM pharmacy ownership target the wrong problem: government rules that raise drug prices and that PBMs can't negotiate away.


The Case of the Missing Sale: The FTC's Personalized-Pricing Blind Spot
In Truth on the Market, CFJ's Jeffrey Depp argues that the FTC's personalized-pricing proposal overlooks the sales that tailored discounts make possible.


CFJ Comments to the FTC on the Proposed Personalized Pricing Policy Statement
In comments to the FTC, CFJ urged the Commission to withdraw or revise its personalized-pricing policy statement and stick to proven deception.


The Epistemic Court: Why Deleting 'Climate Science' Protects Judicial Legitimacy
In RealClearEnergy, CFJ's Jeffrey Depp argues that pulling a contested climate chapter from the federal judiciary's evidence manual protects judicial legitimacy.


Podcast: Agency Power, Antitrust, and the Supreme Court with Ashley Baker
Ashley Baker joins Dr. Vance Ginn on Let People Prosper to discuss Trump v. Slaughter, FTC power, antitrust enforcement and the cost of regulation.


Webinar Video: Congress and the Future of AI: Model Testing, Preemption, and Open Weight Policy
Video: what Congress should do on AI model testing, preemption of state AI laws and open-weight models, with Kevin Frazier, Neil Siefring and Paul Steidler.


Webinar Video: The Paramount Merger Litigation
Video: can state AGs stop Paramount's Warner Bros. Discovery deal? Asheesh Agarwal, Eric Fruits and Michael Toth on the merger litigation.


Certified Uncertain: Why AI Safety Needs Assurance Tests, Not Permission Slips
In Truth on the Market, CFJ's Jeffrey Depp argues that no finite test can certify an evolving AI system as safe, so AI needs continuous assurance, not licensing.

